Astellas Pharma (Astellas Pharma) Interest Expense : $-70 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Astellas Pharma's interest expense for the three months ended in Dec. 2023 was $ -20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-70 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Astellas Pharma's Operating Income for the three months ended in Dec. 2023 was $ 131 Mil. Astellas Pharma's Interest Expense for the three months ended in Dec. 2023 was $ -20 Mil. Astellas Pharma's Interest Coverage for the quarter that ended in Dec. 2023 was 6.67. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Astellas Pharma Interest Expense Historical Data

The historical data trend for Astellas Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Interest Expense Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-11.72

-27.90

-21.48

-41.74

-65.68

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-20.78	-15.50	-19.24	-15.35	-19.66

Astellas Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70 Mil.

Astellas Pharma (OTCPK:ALPMY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Astellas Pharma's Interest Expense for the three months ended in Dec. 2023 was $-20 Mil. Its Operating Income for the three months ended in Dec. 2023 was $131 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $3,221 Mil.

Astellas Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	131.045	/	-19.655
	=	6.67

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Astellas Pharma Inc interest coverage is 1.27, which is low.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.